Tag: targets

Otago researchers studying the COVID-19 virus (SARS-2) have discovered potential target points on its genome, which may contribute to future treatments for the virus. While their laboratory was locked down during the Level 4 period, Ph.D. student Ali Hosseini and Professor Alex McLellan from the Department of Microbiology and Immunology worked from their homes to

Scientists have shown for the first time evidence that early sampling of blood for microorganisms in sepsis is critical to treating the common and potentially fatal condition. In an international study including researchers from the University of British Columbia (UBC), McGill University and Harvard Medical School, scientists found that in order to better treat sepsis,

There is only one existing vaccine for TB and it is not effective in adults. Researchers at the Centenary Institute and University of Sydney will next test their new vaccine in clinical trials with humans. Australian medical researchers from the Centenary Institute and the University of Sydney have successfully developed and tested on mice a

The pharmaceutical company, Cortexyme, Inc. has outlined a trial of potential Alzheimer’s drug that targets toxic substances released by P. gingivalis, a bacteria linked to gum disease. In a poster presented at the Alzheimer’s Association International Conference today (Wednesday, July 17), researchers provided an overview of the development of the drug, known as COR388, and

Every three minutes, a food-related allergic reaction sends someone to the emergency room in the U.S. Currently, the only way to prevent a reaction is for people with food allergies to completely avoid the food to which they are allergic. Researchers are actively seeking new treatments to prevent or reverse food allergies in patients. Recent

A study published recently in the Journal of Clinical Oncology Precision Oncology, an American Society of Clinical Oncology (ASCO) journal, outlines findings from the largest-ever prospective genomic analysis of advanced prostate cancer tumors. Using comprehensive genomic profiling (CGP) to analyze thousands of tumor samples from men with advanced prostate cancers, the researchers identified that 57

(HealthDay)—College students face a much higher risk for the deadly bacterial infection meningitis B, a new analysis shows. Investigators from the U.S. Centers for Disease Control and Prevention found that students who were aged 18 to 24 were 3.5 times more likely to contract meningitis B than their peers who were not in school. The

There has been a decline in the uptake of life-saving treatments among people living with hepatitis C, according to new data released by the Kirby Institute at UNSW Sydney. The data, released ahead of World Hepatitis Day on 28 July, shows that 58,280 people have begun hepatitis C therapy since highly-curative treatments were placed on

Antiretroviral therapies have worked wonders suppressing HIV replication and its progression to AIDS, but their effectiveness is deteriorating due to the constant development of drug resistance in the virus. Now Yale researchers have shown their newly developed compounds maintain anti-HIV activity against drug-resistant mutants better than FDA-approved medications. The new compounds work by inhibiting the

(HealthDay)—The U.S. Food and Drug Administration has launched legal action to stop two stem cell clinics from providing unapproved treatments that have caused serious, long-term harm to some patients. On Wednesday, the FDA filed complaints in federal court seeking permanent injunctions against U.S. Stem Cell Clinic LLC of Sunrise, Fla., and California Stem Cell Treatment

The National Cancer Institute (NCI) estimate that 164,690 people will be diagnosed with prostate cancer in 2018. They suggest that more than 11 percent of men will receive this diagnosis at some point during their lifetime. Treatments for prostate cancer can include radiation therapy, hormone therapy, and chemotherapy. But unfortunately, in many cases, tumors that

Genome-wide association studies (GWAS) have identified more than 150 genetic variations associated with increased risk for breast cancer. Most of these variants are not located in protein-coding gene regions but are assumed to regulate the expression of certain genes. One way to figure out what these variants are doing is to conduct a cis-eQTL analysis.

A new view of a protein frequently mutated in pituitary tumors is overturning conventional wisdom and could point to novel targets for cancer drugs. The protein, a “G protein” called Gαs, initiates messages inside cells. But a single mutation alters Gαs action in a surprising way. The protein’s molecular “off switch” actually switches activity on,

Non-Hodgkin lymphoma, a cancer that is diagnosed in the U.S. more than 70,000 times annually, arises from overly proliferating immune cells within the body’s lymph nodes, which are connected to a network of lymph vessels through which lymphatic fluid flows. The most common type of lymphoma is diffuse large B-cell lymphoma (DLBCL), accounting for about